Patent details
91616 Product Name: Anticorps monoclonal hybride rat-souris (IgG2) sous toutes les formes couvertes par le brevet de base (REMOVAB - Catumaxomab)
Basic Information
- Publication number:
- 91616
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP019822410
- Legal Status:
- Lapsed
- Application number:
- 91616
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/09/512/001-002
- Marketing Authorization Type:
- Marketing Authorization Date:
- 20/04/2009
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
Dates
- Filing date:
- 16/10/2009
- First Marketing Authorization date:
- 20/04/2009
- Grant date:
- 16/12/2009
- Activation date:
- 04/09/2021
- Publication date:
- 16/12/2009
- Lapsed date:
- 04/09/2021
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 20/04/2024
- SPC Extension Expiration:
- 20/04/2024
- Rejection date:
- Withdrawal date:
Owner
- From:
- 16/10/2009
- Name:
- TRION PHARMA GMBH
- Address:
- FRANKFURTER RING 193A, 80807, MÜNCHEN, Germany (DE)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 16/10/2009
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
- Name:
- Dr. Horst Lindhofer
- Address:
- Germany (DE)
Publication
Bulletin
- Bulletin Heading:
- SPC3
- Bulletin edition number:
- 2021/11
- Publication date:
- 08/10/2021
- Description:
- Section E : Supplementary Protection certificates entered into force – IA publication
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|